HMGB1 in sepsis - PubMed (original) (raw)

Review

HMGB1 in sepsis

Ulf Andersson et al. Scand J Infect Dis. 2003.

Abstract

HMGB1 is a member of the high-mobility group protein superfamily that has been widely studied as nuclear proteins that bind DNA, stabilize nucleosomes and facilitate gene transcription. A series of recent discoveries revealed a cytokine activity of HMGB1, that when secreted into the extracellular milieu, mediates downstream inflammatory responses in endotoxemia, arthritis and sepsis. HMGB1 is properly defined as a cytokine because it stimulates proinflammatory responses in monocytes/macrophages, is produced during inflammatory responses in vivo in standardized models of systemic and local inflammation, mediates delayed endotoxin lethality, and is required for the full expression of inflammation in animal models of endotoxemia, sepsis and arthritis. HMGB1 is either actively secreted by monocytes/macrophages or passively released from necrotic cells from any tissue. These pathways are central for the biology of HMGB1 as a cytokine, since they provide key mechanisms that integrate the inflammatory response to infectious and non-infectious cell injuries. Receptor signal transduction of HMGB1 occurs in part through the receptor for advanced glycation end-products (RAGE) expressed on monocytes/macrophages, endothelial cells, neurons and smooth-muscle cells. HMGB1 is a late-acting cytokine, because it first appears in the extracellular milieu 8-12 h after the initial macrophage response to proinflammatory stimuli. Knowledge of the cytokine role of HMGB1 has implications for understanding downstream cytokine cascades, regulation of delayed innate immune responses and targeting treatment towards these processes. Effectiveness of delayed treatment with HMGB1 blockade up to 24 h after induction of experimental sepsis offers a unique window of opportunities to allow rescue from lethal sepsis.

PubMed Disclaimer

Similar articles

• HMGB1 as a DNA-binding cytokine.
  Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. Andersson U, et al. J Leukoc Biol. 2002 Dec;72(6):1084-91. J Leukoc Biol. 2002. PMID: 12488489 Review.
• Role of high mobility group box 1 in inflammatory disease: focus on sepsis.
  Bae JS. Bae JS. Arch Pharm Res. 2012 Sep;35(9):1511-23. doi: 10.1007/s12272-012-0901-5. Epub 2012 Oct 9. Arch Pharm Res. 2012. PMID: 23054707 Review.
• Endogenous HMGB1 is required in endotoxin tolerance.
  Li S, Luo C, Yin C, Peng C, Han R, Zhou J, He Q, Zhou J. Li S, et al. J Surg Res. 2013 Nov;185(1):319-28. doi: 10.1016/j.jss.2013.05.062. Epub 2013 Jun 10. J Surg Res. 2013. PMID: 23866790
• Role of HMGB1 in cardiovascular diseases.
  Li W, Sama AE, Wang H. Li W, et al. Curr Opin Pharmacol. 2006 Apr;6(2):130-5. doi: 10.1016/j.coph.2005.10.010. Epub 2006 Feb 17. Curr Opin Pharmacol. 2006. PMID: 16487750 Free PMC article. Review.
• High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.
  Czura CJ, Yang H, Tracey KJ. Czura CJ, et al. J Infect Dis. 2003 Jun 15;187 Suppl 2:S391-6. doi: 10.1086/374753. J Infect Dis. 2003. PMID: 12792856

Cited by

• Exploring the role of antioxidants in sepsis-associated oxidative stress: a comprehensive review.
  Sahoo DK, Wong D, Patani A, Paital B, Yadav VK, Patel A, Jergens AE. Sahoo DK, et al. Front Cell Infect Microbiol. 2024 Mar 6;14:1348713. doi: 10.3389/fcimb.2024.1348713. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38510969 Free PMC article. Review.
• Clinical chorioamnionitis at term is characterized by changes in the plasma concentration of CHCHD2/MNRR1, a mitochondrial protein.
  Bosco M, Romero R, Gallo DM, Suksai M, Gotsch F, Jung E, Chaemsaithong P, Tarca AL, Gomez-Lopez N, Arenas-Hernandez M, Meyyazhagan A, Al Qasem M, Franchi MP, Grossman LI, Aras S, Chaiworapongsa T. Bosco M, et al. J Matern Fetal Neonatal Med. 2023 Dec;36(2):2222333. doi: 10.1080/14767058.2023.2222333. J Matern Fetal Neonatal Med. 2023. PMID: 37349086
• The exogenous delivery of microRNA-449b-5p using spermidine-PLGA nanoparticles efficiently decreases hepatic injury.
  Hu F, Yang D, Qian B, Fan S, Zhu Q, Ren H, Li X, Zhai B. Hu F, et al. RSC Adv. 2019 Oct 30;9(60):35135-35144. doi: 10.1039/c9ra06129k. eCollection 2019 Oct 28. RSC Adv. 2019. PMID: 35530696 Free PMC article.
• Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate.
  Yang K, Holt M, Fan M, Lam V, Yang Y, Ha T, Williams DL, Li C, Wang X. Yang K, et al. Front Immunol. 2022 Mar 23;13:868679. doi: 10.3389/fimmu.2022.868679. eCollection 2022. Front Immunol. 2022. PMID: 35401579 Free PMC article. Review.
• Analysis of Early Biomarkers Associated with the Development of Critical Respiratory Failure in Coronavirus Disease 2019 (COVID-19).
  Yamada H, Okamoto M, Nagasaki Y, Yoshio S, Nouno T, Yano C, Tanaka T, Watanabe F, Shibata N, Arimizu Y, Fukamachi Y, Zaizen Y, Hamada N, Kawaguchi A, Hoshino T, Morita S. Yamada H, et al. Diagnostics (Basel). 2022 Jan 28;12(2):339. doi: 10.3390/diagnostics12020339. Diagnostics (Basel). 2022. PMID: 35204430 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Taylor & Francis

• Medical

  • MedlinePlus Health Information